Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring

• Viktor von Wyl ,

  * E-mail: viktor.vonwyl@css-institut.ch

  Affiliations University College London, Research Department of Infection and Population Health, London, United Kingdom, CSS Institute for Empirical Health Economics, Lucerne, Switzerland

  ⨯
• Valentina Cambiano,

  Affiliation University College London, Research Department of Infection and Population Health, London, United Kingdom

  ⨯
• Michael R. Jordan,

  Affiliations World Health Organization, Geneva, Switzerland, Tufts University, School of Medicine, Boston, Masschussetts, United States of America

  ⨯
• Silvia Bertagnolio,

  Affiliation World Health Organization, Geneva, Switzerland

  ⨯
• Alec Miners,

  Affiliation London School of Hygiene and Tropical Medicine, London, United Kingdom

  ⨯
• Deenan Pillay,

  Affiliation University College London, Division of Infection and Immunity, London, United Kingdom

  ⨯
• Jens Lundgren,

  Affiliation Copenhagen University Hospital-Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

  ⨯
• Andrew N. Phillips

  Affiliation University College London, Research Department of Infection and Population Health, London, United Kingdom

  ⨯